NCI 8628: a randomized phase 2 study of ziv ‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma

Cancer, EarlyView.

Source: Cancer - October 10, 2018 Category: Cancer & Oncology Authors: Ahmad A. Tarhini, Paul Frankel, Christopher Ruel, Marc S. Ernstoff, Timothy M. Kuzel, Theodore F. Logan, Nikhil I. Khushalani, Hussein A. Tawbi, Kim A. Margolin, Sanjay Awasthi, Lisa H. Butterfield, David McDermott, Alice Chen, Primo N. Lara, Source Type: research